SCHEMBL2864567

SCHEMBL2864567

Nc1ccc2[nH]nc(-c3cc4ccccc4s3)c2c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.48
APP P05067 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
PRKDC P78527 1/20 0.40
MAPK10 P53779 1/20 0.39
IKBKB O14920 1/20 0.38
PLAU P00749 1/20 0.37
ITK Q08881 2/20 0.36
HDAC2 Q92769 1/20 0.35
PIM1 P11309 1/20 0.35
PIM3 Q86V86 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
DCK P27707 1/20 0.34
JAK2 O60674 1/20 0.34
JAK3 P52333 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2866231 0.83 MAPKAPK2 (0.47) MAPKAPK2APPSIRT2SIRT1PIK3CD
SCHEMBL2859049 0.81 MAPK10 (0.43) MAPKAPK2SIRT2SIRT1MAPK10IKBKB
SCHEMBL2863679 0.78 JAK2 (0.44) MAPKAPK2SIRT2SIRT1MAPK10IKBKB
SCHEMBL2861026 0.78 TNIK (0.49) MAPKAPK2SIRT2SIRT1MAPK10ITK
SCHEMBL2861529 0.78 MAPKAPK2 (0.53) MAPKAPK2APPSIRT2SIRT1PIK3CD
SCHEMBL13198221 0.75 SIRT2 (0.41) MAPKAPK2APPSIRT2SIRT1MAPK10
SCHEMBL2863193 0.75 MAPKAPK2 (0.46) MAPKAPK2PIK3CDPIK3CAPIK3CBPIK3CG
Cyclopropanecarboxylic Acid Amide SCHEMBL2857322 0.75 SIRT2 (0.48) MAPKAPK2SIRT2SIRT1MAPK10IKBKB
SCHEMBL13198255 0.75 SIRT2 (0.40) MAPKAPK2SIRT2SIRT1MAPK10IKBKB
SCHEMBL2857326 0.74 PIP5K1C (0.48) MAPKAPK2SIRT2SIRT1MAPK10DCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPKAPK2 18/4885APP 3745/4885SIRT2 1519/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 MAPKAPK2 26/4885APP 4265/4885SIRT2 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.